Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 12/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.46 |
| ▸ | SRC | P12931 | 2/20 | 0.44 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15332507 | 0.85 | TRPA1 (0.45) | TRPA1TGFBR1MAPK14SRCKDM5B | |
| SCHEMBL15341835 | 0.83 | KDM5B (0.48) | TRPA1TGFBR1MAPK14SRCKDM5B | |
| SCHEMBL15984817 | 0.79 | TRPA1 (0.53) | TRPA1TGFBR1MAPK14ARAPP | |
| SCHEMBL19998605 | 0.77 | TRPA1 (0.51) | TRPA1TGFBR1MAPK14ARAPP | |
| SCHEMBL13680555 | 0.76 | TGFBR1 (0.55) | TRPA1TGFBR1MAPK14 | |
| SCHEMBL15344160 | 0.75 | TRPA1 (0.46) | TRPA1TGFBR1MAPK14SRCKDM5B | |
| SCHEMBL15345075 | 0.74 | TRPA1 (0.48) | TRPA1SRCKDM5BARAPP | |
| SCHEMBL15344917 | 0.74 | TRPA1 (0.48) | TRPA1TGFBR1MAPK14SRCKDM5B | |
| SCHEMBL15344151 | 0.74 | TRPA1 (0.48) | TRPA1TGFBR1MAPK14SRCAR | |
| SCHEMBL15345014 | 0.73 | TRPA1 (0.47) | TRPA1SRCKDM5BARAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3070081-B1 | BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION | GILEAD SCIENCES INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-01-21 | — | — | US | disclosed |
| US-8987250-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | TRPA1 4316/4885TGFBR1 4545/4885MAPK14 3189/4885 |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | TRPA1 4316/4885TGFBR1 4545/4885MAPK14 3189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.